Helicobacter pylori infection
Conditions
Interventions
Experimental group (group of susceptibility-guided therapy):Bismuth quadruple treatment containing sensitive antibiotics according to the result of drug resistance test
Control group (group of empirical therapy):Bismuth quadruple treatment containing antibiotics that haven't been used before according to medical history
Observation group:None
Sponsors
Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Sub-study (1) ? Age between 18 and 70; ? Patients who intend to undergo gastroscopy in the hospital; ? Urea breath test (+); ? Agree to participate in this clinical study and sign the informed consent form. Sub-study (2) ? Age between 18 and 70; ? Confirmed H. pylori infection, with =2 of the following 4 tests positive: a. Urea breath test; b. Rapid urease test; c. Staining of gastric mucosal tissues; d. H. pylori culture; ? Agree to participate in this clinical trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Sub-study (1) ? Pregnant or lactating women and patients with mental illness; ? Use of PPIs and P-CABs in the past 2 weeks and antibiotics, bismuth and herbal medicines with antimicrobial effect in the past 4 weeks; ? Previous history of gastric surgery; ? Severe organic diseases of the digestive system, such as malignant tumour of the digestive tract, gastrointestinal bleeding, peptic ulcer with perforation/obstruction, intestinal obstruction, inflammatory bowel disease; ? Severe systemic diseases, such as severe cardiovascular and cerebrovascular diseases, diabetes mellitus, chronic renal insufficiency, connective tissue disease, neurological lesions, etc; ? Any other factors that, in the opinion of the investigator, make the subject unsuitable for enrolment or affect the subject's participation in the study. Sub-study (2) ? Pregnant or lactating women and patients with recent birth plans; ? People with disabilities stipulated by law (blindness, deafness, dumbness, mental disorder, mental disorder, physical disability); ? Those who are allergic to experimental drugs (amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, PPI, bismuth); ? Need for continuous use of adrenocortical steroids, non-steroidal anti-inflammatory drugs and anticoagulants; ? Previous history of gastric surgery; ? Use of PPIs and P-CABs in the past 2 weeks and antibiotics, bismuth and herbal medicines with antimicrobial effect in the past 4 weeks; ? Suspected or confirmed history of alcohol and drug abuse. ? Severe organic diseases of the digestive system, such as malignant tumour of the digestive tract, gastrointestinal bleeding, peptic ulcer with perforation/obstruction, intestinal obstruction, inflammatory bowel disease; ? Severe systemic diseases, such as severe cardiovascular and cerebrovascular diseases, diabetes mellitus, chronic renal insufficiency, connective tissue disease, neurological lesions, etc; ? Any other factors that, in the opinion of the investigator, make the subject unsuitable for enrolment or affect the subject's participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori resistance rate;H. pylori eradiction rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| subject compliance; | — |
Countries
China
Contacts
Public ContactYiqi Du
Changhai Hospital
Outcome results
None listed